Bicara Therapeutics Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
David Raben, MD, separated from employment on May 7, 2026, receiving $530,000 severance (12 months salary continuation) plus 12 months COBRA premium coverage. Simultaneously transitioned to Senior Executive Advisor consultant at $8,000/month through December 31, 2026. Board approved 2026 Inducement Plan (1M shares) on January 28, 2026, then amended June 9, 2026, to increase share reserve by 700,000 to 1.7M shares—both without stockholder approval under NASDAQ Rule 5635(c)(4).
Why this rating
Raben separation + modest consulting retainer is routine turnover. Equity plan expansion (1.7M shares on ~$377M market cap = ~0.45% dilution) is material relative to plan reserves but typical for biotech. No transformational deal or going-concern event.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.